Kras G12V TCR therapy (immuxell)

N/A

Report date: 2023/12/26 13:38:22

Base Information

Drug NameKras G12V TCR therapy (immuxell)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionKRAS G12V inhibitors
TargetsKRAS G12V
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Immuxell Biotech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Immuxell Biotech Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A